https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1132201/full
Frontiers | Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics...
Background: Myasthenia gravis (MG) is an autoimmune disease with acquired neuromuscular junction transmission disorders. In the last two decades, various pat...
for myasthenia gravisknowledge mappingglobal trends
https://www.cochrane.org/de/evidence/CD006986_acetylcholinesterase-inhibitor-treatment-myasthenia-gravis
Acetylcholinesterase inhibitor treatment for myasthenia gravis | Cochrane
for myasthenia gravisacetylcholinesteraseinhibitortreatmentcochrane
https://www.pharmaceutical-technology.com/data-insights/gefurulimab-alexion-pharmaceuticals-myasthenia-gravis-likelihood-of-approval-2/
Gefurulimab by Alexion Pharmaceuticals for Myasthenia Gravis: Likelihood of Approval
Sep 9, 2024 - Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis.
for myasthenia gravisalexion pharmaceuticalslikelihoodapproval